AGN - Allergan plc

NYSE - NYSE Delayed Price. Currency in USD
158.43
-1.80 (-1.12%)
At close: 4:01PM EDT
Stock chart is not supported by your current browser
Previous Close160.23
Open159.99
Bid0.00 x 800
Ask0.00 x 800
Day's Range158.00 - 161.34
52 Week Range142.81 - 256.80
Volume2,501,792
Avg. Volume3,175,867
Market Cap53.718B
Beta1.23
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield2.88 (1.73%)
Ex-Dividend Date2018-02-27
1y Target EstN/A
Trade prices are not sourced from all markets
  • Walmart, Allergan and Alphabet are the Yahoo Finance charts of the day.
    Yahoo Finance Video3 days ago

    Walmart, Allergan and Alphabet are the Yahoo Finance charts of the day.

    Let's check out the Yahoo Finance charts of the day. Walmart (WMT): Shares are down in early trade,  around 2%. The retail chain reported fiscal first-quarter earnings that beat expectations on the top and bottom lines, as its e-commerce business rebounded. Allergan (AGN): Shares are up here, around 1%. The global pharmaceutical company was sued by four large U.S. retailers that accused the drugmaker of antitrust violations for trying to stop rivals from selling generic versions of Restasis, its medication to treat dry-eye disease. Alphabet (GOOG): Shares are down here,  around .32%.  Alphabet's YouTube said it will launch a new music streaming service, YouTube Music, next week and unveil soon a premium service that will charge more for its original shows. For more on today's big stock movers check out the Final Round, live at 3:55 p.m. ET, right here on Yahoo Finance.

  • Big Pay, Little Return
    Yahoo Finance Video6 days ago

    Big Pay, Little Return

    Top CEOs get paid millions, but new study shows that does not always lead to a good return for investors. Yahoo Finance's Seana Smith, Andy Serwer and Julia La Roche discuss.

  • MARKETS: Biotech and pharma stocks could be the key to the market bull case
    Yahoo Finance Video10 days ago

    MARKETS: Biotech and pharma stocks could be the key to the market bull case

    Yahoo Finance's Jared Blikre joins Seana Smith from the floor of the New York Stock Exchange to discuss the latest market moves.

  • Top Research Reports for Walmart, AT&T & Novo Nordisk
    Zacks2 days ago

    Top Research Reports for Walmart, AT&T & Novo Nordisk

    Top Research Reports for Walmart, AT&T & Novo Nordisk

  • David Tepper gets US approval to take activist stance on Allergan, if he wants it
    CNBC2 days ago

    David Tepper gets US approval to take activist stance on Allergan, if he wants it

    FTC approval gives Tepper's Appaloosa Management flexibility if it decides it wants to be more than a passive investor.

  • TheStreet.com3 days ago

    Facebook Directors Face New Challenges; Allergan Talks Botox Competitors--ICYMI

    Markets turned to the red on Thursday amid the last big push of earnings for the second quarter, and while global energy markets remained hot as oil prices continue to rise, for better or worse. proved many investors wrong after its first quarter earnings, but as its annual meeting approaches the company is again feeling the heat. The two major investor advisory firms this week urged Facebook shareholders to vote against several of the company's directors at its May 31 annual meeting.

  • Appaloosa gets permission for activist stance with Allergan stake
    Reuters3 days ago

    Appaloosa gets permission for activist stance with Allergan stake

    David Tepper's Appaloosa Management and two of his funds received Federal Trade Commission clearance earlier this week that could clear the way for the billionaire to become an activist investor in drugmaker Allergan Plc. Tepper received the Hart-Scott-Rodino anti-trust clearances on Wednesday, according to the FTC's website. Wells Fargo analyst David Maris said in a research note that Allergan "indicated this clearance provides flexibility to the filer as to whether they want take an activist approach to the investment or not." Tepper's Appaloosa LP increased its stake in Allergan to 3.7 million shares from around 3.5 million shares over the last quarter, the firm said in a filing with the Securities and Exchange Commission on Tuesday.

  • Appaloosa gets permission for activist stance with Allergan stake
    Reuters3 days ago

    Appaloosa gets permission for activist stance with Allergan stake

    David Tepper's Appaloosa Management and two of his funds received Federal Trade Commission clearance earlier this week that could clear the way for the billionaire to become an activist investor in drugmaker Allergan Plc. Tepper received the Hart-Scott-Rodino anti-trust clearances on Wednesday, according to the FTC's website. Tepper's Appaloosa LP increased its stake in Allergan to 3.7 million shares from around 3.5 million shares over the last quarter, the firm said in a filing with the Securities and Exchange Commission on Tuesday.

  • TheStreet.com3 days ago

    Allergan's Meury Talks Market Expansion in Aesthetics

    Botox faces a delay in getting to market, Allergan is anything but frozen. "Of course, it's always interesting when a company takes more time to get to market," Allergan chief commercial officer William Meury said at the Bank of America healthcare conference in Las Vegas on Thursday, May 17. Meury's appearance at the conference came a day after competitor Evolus Inc.

  • Walmart under pressure, Allergan's up, Alphabet dips
    Yahoo Finance3 days ago

    Walmart under pressure, Allergan's up, Alphabet dips

    Walmart, Allergan and Alphabet are the Yahoo Finance charts of the day.

  • Walgreen, Kroger, Albertsons, HEB sue Allergan over dry-eye drug
    Reuters4 days ago

    Walgreen, Kroger, Albertsons, HEB sue Allergan over dry-eye drug

    By Jonathan Stempel NEW YORK (Reuters) - Allergan Inc was sued on Wednesday by four large U.S. retailers that accused the drugmaker of antitrust violations for trying to stop rivals from selling generic versions of Restasis, its medication to treat dry-eye disease. Walgreen Co, Kroger Co, Albertsons Cos and HEB Grocery Co accused Allergan of illegally preserving its monopoly by obtaining illegal patents, suing rivals that challenged those patents and transferring the patents to a sovereign Native American tribe, New York's Saint Regis Mohawk Tribe, to escape scrutiny by U.S. courts.

  • Walgreen, Kroger, Albertsons, HEB sue Allergan over dry-eye drug
    Reuters4 days ago

    Walgreen, Kroger, Albertsons, HEB sue Allergan over dry-eye drug

    Allergan Inc was sued on Wednesday by four large U.S. retailers that accused the drugmaker of antitrust violations for trying to stop rivals from selling generic versions of Restasis, its medication to treat dry-eye disease. Walgreen Co, Kroger Co, Albertsons Cos and HEB Grocery Co accused Allergan of illegally preserving its monopoly by obtaining illegal patents, suing rivals that challenged those patents and transferring the patents to a sovereign Native American tribe, New York's Saint Regis Mohawk Tribe, to escape scrutiny by U.S. courts.

  • Reuters4 days ago

    Evolus investors frown as FDA declines to approve Botox rival

    U.S. health regulators on Wednesday declined to approve Evolus Inc's rival product to Allergan Plc's Botox, citing deficiencies related to the chemistry and manufacturing of its potential treatment for frown lines sending its shares down as much as 35 percent. The deficiencies that were communicated by the U.S. Food and Drug Administration in a so-called complete response letter were "manageable", according to CEO Moatazedi, who joined the company earlier this month after serving as U.S. head of Allergan's medical aesthetics business.

  • Teva’s Debt Reduction Plans Progress, Targets Are on Track
    Market Realist4 days ago

    Teva’s Debt Reduction Plans Progress, Targets Are on Track

    Teva Pharmaceutical (TEVA) has been working towards paying down the high level of debt on its balance sheet. Teva obtained the debt in 2016 to fund the acquisition of Allergan’s (AGN) generic business. At the end of fiscal 2017, Teva had a net debt of $31.5 billion on its balance sheet.

  • Why Evolus, Inc. Is Crashing Today
    Motley Fool4 days ago

    Why Evolus, Inc. Is Crashing Today

    Shares swoon after the FDA gives the thumbs down to its lead compound. Here's what investors need to know.

  • The Wall Street Journal6 days ago

    [$$] CEO Pay and Performance Often Don't Match Up

    The better the company and its shareholders do, the more the top boss should be paid, or so the pay-for-performance mantra goes. In reality, CEO pay and performance often don’t match up, and 2017 was no exception. Among S&P 500 CEOs who got raises last year, the 10% who received the biggest pay increases scored—as a group—in the middle of the pack in terms of total shareholder return, according to a Wall Street Journal analysis of data from MyLogIQ LLC and Institutional Shareholder Services.

  • 6 Days Left To Allergan plc (NYSE:AGN)’s Ex-Dividend Date, Is It Worth Buying?
    Simply Wall St.11 days ago

    6 Days Left To Allergan plc (NYSE:AGN)’s Ex-Dividend Date, Is It Worth Buying?

    Shares of Allergan plc (NYSE:AGN) will begin trading ex-dividend in 6 days. To qualify for the dividend check of $0.72 per share, investors must have owned the shares prior toRead More...

  • Musk Meltdown Underscores Art of Keeping Earnings Calls Dull
    Bloomberg11 days ago

    Musk Meltdown Underscores Art of Keeping Earnings Calls Dull

    From the tedious disclaimers at the outset about “forward-looking statements,” to the desiccated remarks read by leaden financial officers, to the mealy mouthed questions posed by unctuous analysts, the calls tend to emit a tonal range so monotonous that you can listen to hundreds of the proceedings without hearing a single memorable thing. Elon Musk’s recent unruly performance during Tesla’s earnings call -- where he bizarrely chastised analysts, telling them among things that “boring, bonehead questions are not cool” -- was a reminder of just how seldomly these rituals of corporate pageantry go off the rails. “You never want to see your management representatives fly off the handle with investors,” said Christopher King, vice president of investor relations at Windstream Holdings Inc., which provides telecom services in rural areas.

  • Bloomberg11 days ago

    How Companies Keep Most Earnings Calls So Incredibly Boring

    From the tedious disclaimers at the outset about “forward-looking statements,” to the desiccated remarks read by leaden financial officers, to the mealy mouthed questions posed by unctuous analysts, the calls tend to emit a tonal range so monotonous that you can listen to hundreds of the proceedings without hearing a single memorable thing. Elon Musk’s recent unruly performance during Tesla’s earnings call -- where he bizarrely chastised analysts, telling them among things that “boring, bonehead questions are not cool” -- was a reminder of just how seldomly these rituals of corporate pageantry go off the rails.

  • Benzinga11 days ago

    Morgan Stanley Turns Bearish On Ironwood Pharma, Lowers Linzess Sales Estimate

    Commercial stage biopharma company Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD )'s Linzess, which it markets along with Allergan plc (NYSE: AGN ) in the U.S., is a major revenue earner for the company. ...

  • How $6 billion generic drug company merger could affect this East Bay city and Roche
    American City Business Journals11 days ago

    How $6 billion generic drug company merger could affect this East Bay city and Roche

    The headquarters of the combined company is the East Coast, not the East Bay, but Hayward could see more manufacturing work.

  • TheStreet.com12 days ago

    Allergan Expects to Finish Strategic Review Quickly, CFO Says

    expects to wrap up its strategic review shortly, according to CFO Matthew Walsh. The drugmaker's management and board are "working with multiple advisers with a sense of urgency," Walsh said Tuesday, May 8, at the Deutsche Bank healthcare conference in Boston. Allergan on April 19 indicated it was considering an offer for Shire plc. Hours later, however, Allergan reversed course and said it was no longer interested in pursuing the company.

  • Merck’s Segment-Wise Performance in 1Q18
    Market Realist12 days ago

    Merck’s Segment-Wise Performance in 1Q18

    Merck’s (MRK) products are classified into four business segments: Human Pharmaceutical, Animal Health, Healthcare Services, and Alliances. Merck’s revenue grew 6% to ~$10.0 billion in 1Q18, driven by 3% operating revenue growth and a 3% boost by foreign exchange.

  • Get Ready for 'Brotox'
    Bloomberg12 days ago

    Get Ready for 'Brotox'

    Allergan is rolling out a new advertising campaign aimed at getting men to use the wrinkle-smoothing treatment Botox. The blockbuster drug has been used by women for years, but that market is now getting ...

  • How Analysts View Allergan after Its 1Q18 Earnings
    Market Realist12 days ago

    How Analysts View Allergan after Its 1Q18 Earnings

    Allergan (AGN) surpassed Wall Street analysts’ estimates for earnings per share (or EPS) and revenues, reporting EPS of $3.74 on revenues of $3.7 billion during 1Q18. Analysts expect Allergan’s top line to fall 3.3% to ~$3.9 billion in 2Q18. Its earnings per share are expected to reach $4.03 in 2Q18. The chart below shows analysts’ recommendations over the last 12 months.